Table 6. Currently approved indications of biologics for severe asthma in Korea.

Biologics	Action	Dose	Interval (wk)	Route	Indication
Omalizumab (Xolair®)	Anti-IgE	0.016 mg/kg per IU	2 or 4	SC	≥ 6 years old; positive allergy testing (allergic asthma); IgE: 30–700 IU/mL
Mepolizumab (Nucala®)	Anti-IL5	100 mg	4	SC	≥ 18 years old; AEC ≥ 150 cells/µL or ≥ 300 cells/µL at least once a year
Reslizumab (Cinqair®)	Anti-IL5	3 mg/kg	4	IV	≥ 18 years old; AEC ≥ 400 cells/µL
Benralizumab (Fasenra®)	Anti-IL5R	30 mg	8*	SC	≥ 18 years old; severe eosinophilic asthma
Dupilumab (Dupixent®)	Anti-IL4Rα	200 mg†	2	SC	≥ 12 years old; AEC ≥ 150 cells/µL or FeNO ≥ 25 ppb
		300 mg‡	2	SC	With OCS-dependent or moderate-to-severe atopic dermatitis

SC, subcutaneous; IV, intravenous; IgE, immunoglobulin E; IL, interleukin; AEC, absolute blood eosinophil count; FeNO, fractional exhaled nitric oxide; OCS, oral corticosteroids.

^*Every 4 weeks for the first 3 doses, followed by every 8 weeks for maintenance; ^†For the first cycle, 400 mg (two 200 mg injections); ^‡For the first cycle, 600 mg (two 300 mg injections).